[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52

Advertisement
4. Irving JA, McCluggage WG: Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis. Adv Anat Pathol; 2007 Sep;14(5):305-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis.
  • Ovarian lesions composed of spindle cells comprise a heterogeneous group; most are neoplastic but several non-neoplastic conditions are also composed of spindle cells.
  • This review discusses the main differential diagnoses of an ovarian spindle cell lesion, especially concentrating on the recent literature.
  • The majority of ovarian spindle cell lesions fall into the broad category of fibromatous neoplasms whereas others in the sex cord-stromal group may also be composed of spindle cells, including thecomas, granulosa, and Sertoli-Leydig cell tumors and rarer neoplasms, such as sclerosing stromal tumor and signet-ring stromal tumor.
  • In the recent past there have been several major contributions on various aspects of ovarian spindle cell lesions, including cellular and mitotically active cellular fibromatous lesions, smooth muscle neoplasms, and metastatic gastrointestinal stromal tumors.
  • Other mesenchymal or epithelial tumors and mixed epithelial and mesenchymal neoplasms may also enter into the differential diagnosis of an ovarian spindle cell lesion.
  • Several non-neoplastic lesions may be composed of spindle cells, including massive edema, ovarian fibromatosis, stromal hyperplasia, and stromal hyperthecosis.
  • Morphology remains the mainstay in diagnosis but immunohistochemistry may be invaluable in certain circumstances, one example being the identification of a metastatic gastrointestinal stromal tumor within the ovary.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Pathology, Surgical / methods. Pathology, Surgical / trends

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717430.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 101
  •  go-up   go-down


5. Emerson RE, Wang M, Roth LM, Zheng W, Abdul-Karim FW, Liu F, Ulbright TM, Eble JN, Cheng L: Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors. Int J Gynecol Pathol; 2007 Oct;26(4):368-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors.
  • Sertoli-Leydig cell tumors (SLCT) comprise less than 1% of ovarian tumors.
  • The nature of the Leydig cells has been a subject of controversy and it is unclear whether they are clonally related to the neoplasm or instead proliferate as a non-neoplastic response to the Sertoli-cell component.
  • Twelve ovarian SLCT were identified and hematoxylin and eosin and unstained sections were prepared from formalin-fixed, paraffin-embedded tissue blocks.
  • Tissue samples were microdissected from normal tissue, the Sertoli cell component, and the Leydig cell tumor component using the laser capture microdissection method.
  • LOH and/or nonrandom X-chromosome inactivation was observed in at least 1 of the 6 amplified loci in the Leydig cell component of 10 of the 12 tumors.
  • LOH and nonrandom X-chromosome inactivation patterns of the Sertoli cell component and Leydig cell component were compared.
  • Concordant allelic loss and/or matching X-chromosome inactivation patterns were observed in 8 (67%) of the 12 tumors.
  • In 7 of these tumors similar LOH or X-chromosome inactivation was observed at 1 site.
  • In 1 tumor similar LOH and/or X-chromosome inactivation was observed at 2 sites.
  • Three tumors had heterologous components.
  • The heterologous components similarly shared LOH/X-chromosome inactivation with the Sertoli cell components at 1 site in 1 case and 2 sites in 2 cases.
  • These data suggest that, at least in some cases, the Leydig cell component of SLCT is neoplastic rather than reactive in nature, and shares a common clonal origin with the coexisting Sertoli cell component.
  • Similarly, the heterologous components, when present, appear to share clonal origin with the Sertoli cell components.
  • [MeSH-major] Leydig Cells / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / genetics. Sertoli-Leydig Cell Tumor / pathology

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885485.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Greenbaum D, Friedel D: Unanticipated findings at bariatric surgery. Surg Obes Relat Dis; 2005 Jan-Feb;1(1):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In only three cases (one case each of carcinoid of the appendix, Sertoli-Leydig cell tumor of the ovary, and serous cystadenocarcinoma of the ovary) would there have been a significant difference in the patient's prognosis had the problem been left undiagnosed.
  • [MeSH-major] Incidental Findings. Obesity, Morbid / epidemiology. Ovarian Diseases / epidemiology. Peritoneal Diseases / epidemiology
  • [MeSH-minor] Adult. Aged. Comorbidity. Diverticulitis, Colonic / epidemiology. Female. Humans. Male. Middle Aged. Sigmoid Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925197.001).
  • [ISSN] 1550-7289
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Young RH: Testicular tumors--some new and a few perennial problems. Arch Pathol Lab Med; 2008 Apr;132(4):548-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular tumors--some new and a few perennial problems.
  • The histopathology of testicular tumors is presented, emphasizing new, unusual, or underemphasized aspects.
  • Within the category of seminoma of the usual type, the recent literature has drawn attention to the presence in occasional tumors of solid or hollow tubules or spaces of varying sizes and shape that may result in cribriform or microcystic patterns, causing potential confusion with other neoplasms, most notably Sertoli cell tumor or yolk sac tumor.
  • Although regions of typical neoplasia and awareness of this phenomenon usually will be diagnostic, immunohistochemistry may play a role in excluding Sertoli cell tumor or yolk sac tumor.
  • Although immunohistochemistry can play an undoubted helpful role in this and selected other areas of testicular tumor evaluation, careful evaluation of the gross and routine microscopic features will solve the vast majority of diagnostic problems.
  • Spermatocytic seminoma remains a crucial pitfall in diagnosis, and the pathologist must always be alert to the possible diagnosis when looking at a seminomatous neoplasm, particularly in an older patient, although about one third of these tumors occur in the usual seminoma age range.
  • The enigmatic and picturesque tumor, polyembryoma, which virtually never occurs in pure form but may be a confusing component of a variety of mixed germ cell tumors, is discussed and illustrated.
  • The phenomenon of burnt-out germ cell neoplasia is also briefly noted and an excellent recent contribution is referred to.
  • Within the sex cord-stromal family of neoplasms, recent contributions and elaborations of unusual morphologic features of Leydig cell tumors and Sertoli cell tumors are presented.
  • Within the Leydig cell family, cyst formation, adipose metaplasia, calcification or ossification, and spindle cell patterns may be particularly confusing, and in the Sertoli cell family, a great array of patterns caused by differing admixtures of tubular, solid, and stromal components occur.
  • The peculiar lesion, intratubular large cell hyalinizing Sertoli cell tumor, of young boys with Peutz-Jeghers syndrome, is briefly discussed.
  • Some of the problems in the family of hematopoietic neoplasms are reviewed, these processes posing diverse problems in differential diagnosis and their correct recognition having crucial therapeutic implications.
  • Although secondary tumors to the testis have not received the same attention in the literature as the similar phenomenon in the female gonad, remarkable examples of testicular spread of diverse neoplasms, usually carcinoma but rarely melanoma, are seen, and the pathologist should be alert to this possibility, particularly when examining an unusual morphology in an older patient.
  • Finally, a few comments are made on the common paratesticular neoplasm, the adenomatoid tumor, highlighting its varied patterns and recent description of some of the issues that may arise when they undergo total or subtotal infarction.
  • [MeSH-major] Pathology / education. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / pathology. Diagnosis, Differential. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Humans. Male. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / pathology. Seminoma / diagnosis. Seminoma / pathology. Teratoma / diagnosis. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384207.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


8. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Incidentally, the left ovary revealed a well differentiated sertoli leydig cell tumor.
  • Its simultaneous occurrence with an ovarian sertoli leydig cell tumor has not been reported in English literature so far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Alam K, Maheshwari V, Rashid S, Bhargava S: Bilateral Sertoli-Leydig cell tumor of the ovary: a rare case report. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):97-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Sertoli-Leydig cell tumor of the ovary: a rare case report.
  • Sertoli leydig cell tumors also known as arrhenoblastoma, are a rare member of the sex cord-stromal tumor group of ovarian and testicular cancers, comprising less than 1% of all ovarian tumors, which occur in young adults and are almost always unilateral.
  • We hereby report a case of a 17-year-old female presenting with a short history of irregular menses and an abdominal lump, which was histologically proven to be a bilateral sertoli leydig cell tumor of the ovary, an exceptionally rare entity in itself.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovary / pathology. Sertoli-Leydig Cell Tumor / diagnosis. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136796.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM: Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol; 2009 Apr;113(1):86-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
  • OBJECTIVE: Given the paucity of data regarding the patterns of metastasis from ovarian sex cord-stromal tumors (SCSTs), we sought to determine the risk of lymph node metastasis in patients with SCSTs.
  • METHODS: A retrospective chart review was performed after clinical and pathology databases were queried for ovarian SCST patients who were treated at our institution between 1985 and 2005.
  • RESULTS: We identified 262 patients with pathology-confirmed ovarian SCSTs; 5 had additional non-stromal histology and were excluded, leaving 257 evaluable patients.
  • Of these patients, 178 had adult granulosa cell tumors, 27 had juvenile granulosa cell tumors, 31 had Sertoli-Leydig cell tumors, 6 had sex cord tumors with annular tubules, 13 had mixed SCSTs, and 2 had SCSTs not otherwise specified.
  • Our evaluation showed that 111 patients underwent a complete or partial staging procedure; 75 had stage I disease, 11 had stage II disease, and 25 had stage III disease.
  • Of 117 patients whose disease eventually recurred, 6 patients (5.1%) had nodal metastases at the time of recurrence.
  • CONCLUSIONS: Lymph node metastasis in ovarian SCSTs is rare.
  • These findings suggest that lymphadenectomy may be omitted when staging patients with ovarian SCSTs.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Soini Y, Talvensaari-Mattila A: Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol; 2006 Oct;25(4):330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types.
  • In this study, 60 different types of ovarian lesions, mainly consisting of ovarian neoplasms, were studied for the expression of claudins 1, 4, 5, and 7.
  • Strong expression of claudins 1, 4, and 7 was seen in benign and malignant epithelial ovarian tumors.
  • Expression of claudin 5, reported to be mainly present in endothelial cells, was seen in ovarian epithelial tumors, but with a significantly lower frequency than claudins 1, 4, and 7.
  • On the contrary, sex-cord stromal tumors and cysts, such as fibromas/thecomas, Sertoli-Leydig cell tumors, granulosa cell tumors, and follicular and luteinized cysts were mainly negative for claudins 1, 4, 5, and 7.
  • Interestingly, adenomatoid tumors did not express claudin 5, which is in agreement with their non-endothelial nature.
  • The results show that claudins 1, 4, and 7 are mainly expressed in ovarian epithelial tumors and can thus be used to indicate epithelial differentiation in them.
  • However, this claudin can be used to differentiate adenomatoid tumors from vascular lesions.
  • No significant difference was seen between epithelial benign and malignant lesions, except for claudin 5, which seemed stronger in malignant epithelial tumors.
  • [MeSH-major] Membrane Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adenomatoid Tumor / chemistry. Brenner Tumor / chemistry. Carcinoma / chemistry. Claudin-1. Claudin-4. Claudin-5. Claudins. Dysgerminoma / chemistry. Female. Humans. Immunohistochemistry. Krukenberg Tumor / chemistry. Ovarian Cysts. Sex Cord-Gonadal Stromal Tumors / chemistry. Teratoma / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990707.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


12. Cathro HP, Stoler MH: The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol; 2005 Feb;36(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
  • Calretinin has been proposed as a novel marker of ovarian sex cord-stromal tumors (SCST); this study aims to determine whether calretinin can complement or supplant the established utility of inhibin in the differential diagnosis of SCST.
  • WT1 has been shown to be expressed in ovarian serous, but not mucinous neoplasms; its expression in a variety of ovarian tumors is also examined.
  • Formalin-fixed, paraffin-embedded archival tissues from 111 primary ovarian tumors were analyzed with commercially available antibodies using semi-automated immunohistochemistry.
  • Of 27 SCST, 56% were calretinin and 56% inhibin positive overall; 90% of granulosa cell tumors, 57% of Sertoli-Leydig cell tumors, 33% of thecomas, and 14% of fibromas were calretinin positive.
  • Inhibin was expressed in 60% of granulosa cell tumors, 71% of Sertoli-Leydig cell tumors, 43% of fibromas, and 33% of thecomas.
  • Of 35 surface epithelial tumors (SET), 8% of serous papillary tumors were calretinin positive, whereas 8% of serous papillary tumors and 13% of poorly differentiated carcinomas expressed inhibin.
  • WT1 was expressed in 29% of all endometrioid carcinomas, 10% of borderline mucinous tumors, and no mucinous carcinomas; however, most of the other SETs were positive (77% serous papillary and 88% poorly differentiated carcinomas).
  • Among the SCST, WT1 stained only granulosa cell tumors (75%), though often weakly or variably.
  • Calretinin has only slightly greater sensitivity (76% versus 65%) and equal specificity to inhibin (92%) in the differential staining of granulosa or Sertoli-Leydig cell tumors, that is, nonstromal SCST.
  • Although WT1 should be reliably positive in non-mucinous SET, staining of granulosa cell tumors and lack of expression in a sizable subset of endometrioid carcinomas may confound interpretation.
  • [MeSH-major] Adenocarcinoma / metabolism. Inhibins / metabolism. Ovarian Neoplasms / metabolism. S100 Calcium Binding Protein G / metabolism. Sex Cord-Gonadal Stromal Tumors / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Calbindin 2. Cell Count. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754297.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / WT1 Proteins; 57285-09-3 / Inhibins
  •  go-up   go-down


13. Chan JK, Zhang M, Kaleb V, Loizzi V, Benjamin J, Vasilev S, Osann K, Disaia PJ: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol; 2005 Jan;96(1):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
  • OBJECTIVE: To evaluate prognostic factors that impacts the survival of women with sex cord stromal tumors of the ovary (SCST).
  • METHODS: Cases were identified from tumor registry databases at three academic institutions between 1975 and 2003.
  • RESULTS: Eighty-three women (median age: 49 years) with SCST of the ovary, including 73 with granulosa and 10 with Sertoli-Leydig cell tumors were identified.
  • The median and 5-year disease-specific survival of women with stage I-II vs. III-IV was 180 months and 85% compared to 58 months and 48%, respectively (P = 0.012).
  • Furthermore, age <50 (P = 0.003), premenopausal status (P = 0.013), tumor size < 10 cm (P = 0.003), lack of lymph node invasion (P < 0.0005), and absence of residual disease (P = 0.002) were all significant predictors for improved survival.
  • In multivariate analysis, age <50, smaller tumor size, and absence of residual disease remained as independent prognostic factors.
  • CONCLUSIONS: Age <50, smaller tumor size, and absence of residual disease are important predictors for improved survival in patients with SCST of the ovary.
  • [MeSH-major] Ovarian Neoplasms / mortality. Sex Cord-Gonadal Stromal Tumors / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Registries. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589602.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Martinez-Aguayo A, Rocha A, Rojas N, García C, Parra R, Lagos M, Valdivia L, Poggi H, Cattani A, Chilean Collaborative Testicular Adrenal Rest Tumor Study Group: Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab; 2007 Dec;92(12):4583-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia.
  • CONTEXT: Infertility observed in adult males with congenital adrenal hyperplasia (CAH) has been associated with testicular adrenal rest tumors (TART) that may originate during childhood.
  • OBJECTIVE: Our objective was to describe the prevalence of TART and Sertoli and Leydig cell function in a group of boys aged 2-10 yr with CAH and to compare prevalence with that of a control group.
  • METHODS: We studied 19 subjects in the CAH group and, as a control group, 13 boys from the community that did not have testicular diseases.
  • Inhibin B and anti-Müllerian hormone were used as Sertoli cell markers.
  • The ratio between basal testosterone levels and testosterone levels 72 h after beta-human chorionic gonadotropin (5000 U/m2) treatment [(T72- T0)/T0] was used to evaluate Leydig cell response.
  • [MeSH-major] Adrenal Hyperplasia, Congenital / physiopathology. Adrenal Rest Tumor / physiopathology. Leydig Cells / physiology. Sertoli Cells / physiology. Testicular Neoplasms / physiopathology


15. McClean GE, Kurian S, Walter N, Kekre A, McCluggage WG: Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumour: a more than coincidental association of two rare neoplasms? J Clin Pathol; 2007 Mar;60(3):326-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumour: a more than coincidental association of two rare neoplasms?
  • A case in which an embryonal rhabdomyosarcoma of the cervix and an ovarian Sertoli-Leydig cell tumour of intermediate differentiation occurred in a 13-year-old girl is described.
  • The reason for this association, which is thought to be more than coincidental, is not known, although an underlying genetic abnormality is a possibility.
  • The ovarian tumour in this case was characterised by the presence of foci of cells with extremely pleomorphic nuclei, which initially raised the possibility of metastatic rhabdomyosarcoma.
  • These were interpreted as foci of bizarre nuclei within the Sertoli-Leydig cell tumour.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology. Sertoli-Leydig Cell Tumor / pathology. Uterine Cervical Neoplasms / pathology


16. Tandon R, Goel P, Saha PK, Takkar N, Punia RP: A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element. MedGenMed; 2007;9(4):44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Ovariectomy / methods. Rare Diseases. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Reprod Med. 2001 May;46(5):493-6 [11396379.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2004 Feb;17(1):49-52 [15010040.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):91-3 [15027740.001]
  • [Cites] Am J Obstet Gynecol. 1976 Jun 1;125(3):402-11 [1275030.001]
  • [Cites] Arch Gynecol Obstet. 2001 Jan;264(4):206-8 [11205710.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):543-69 [3911780.001]
  • [Cites] Obstet Gynecol. 1987 Nov;70(5):765-9 [3658288.001]
  • [Cites] Obstet Gynecol. 1996 Apr;87(4):527-31 [8602303.001]
  • [Cites] Am J Surg Pathol. 1984 Jun;8(6):405-18 [6731664.001]
  • (PMID = 18311394.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2234306
  •  go-up   go-down


17. Kawatra V, Mandal S, Khurana N, Aggarwal SK: Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl. J Obstet Gynaecol Res; 2009 Feb;35(1):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl.
  • Sertoli-Leydig cell tumors are rare sex cord-stromal neoplasms that account for <0.2% of ovarian tumors.
  • These tumors with a retiform pattern pose difficult diagnostic problems, with the majority being misinterpreted as serous papillary cystadenocarcinoma and endodermal sinus tumor.
  • Retiform pattern Sertoli-Leydig cell tumor seen mostly in young patients is clinically malignant and has a worse prognosis, underlining the importance of recognition of this histopathologic entity.
  • Described here is a rare case of ovarian Sertoli-Leydig cell tumor with retiform pattern in a 4-year-old child without any endocrine manifestations.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215568.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Cotte B, Gallot D, Ledoux-Pilon A, Dechelotte P, Rivoire C, Canis M, Mage G: [The use of ultrasonographic 3D power Doppler to describe an ovarian Sertoli-Leydig cell tumor]. Gynecol Obstet Fertil; 2008 May;36(5):532-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of ultrasonographic 3D power Doppler to describe an ovarian Sertoli-Leydig cell tumor].
  • [Transliterated title] Description échographique d'une tumeur ovarienne de Sertoli-Leydig à l'aide du doppler énergie tridimensionnel.
  • We report one case of unilateral ovarian Sertoli-Leydig tumor with intermediate grade and heterologous element, in a young woman with clinical and biological typical presentation.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462975.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Herrera JD, Davidson JA, Mestman JH: Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature. Endocr Pract; 2009 Mar;15(2):149-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature.
  • OBJECTIVE: To report a case of hyperandrogenism attributable to the presence of an adrenal adenoma secreting dehydroepiandrosterone sulfate (DHEA-S) and an ovarian Sertoli-Leydig cell tumor secreting testosterone in a postmenopausal woman.
  • Laboratory tests showed elevated levels of total testosterone (348 ng/dL) and DHEA-S (2,058 microg/dL), and a left adrenal tumor (3 by 4 cm) was detected on abdominal computed tomographic scan.
  • Laparoscopic left adrenalectomy was performed, and the pathologic diagnosis was adrenal adenoma.
  • Transvaginal ultrasonography disclosed an ovarian tumor.
  • Bilateral oophorectomy was performed, and an ovarian Sertoli-Leydig cell tumor was diagnosed.
  • CONCLUSION: After extensive review of the literature, we believe that this is the first reported case of a coincidental DHEA-S-secreting adrenal adenoma and a testosterone- secreting ovarian Leydig cell tumor causing signs of virilization.
  • [MeSH-major] Adrenocortical Adenoma / metabolism. Dehydroepiandrosterone Sulfate / metabolism. Hyperandrogenism / diagnosis. Hyperandrogenism / etiology. Leydig Cell Tumor / metabolism. Testosterone / metabolism

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adrenal adenoma .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289327.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  • [Number-of-references] 13
  •  go-up   go-down


23. Caringella A, Loizzi V, Resta L, Ferreri R, Loverro G: A case of Sertoli-Leydig cell tumor in a postmenopausal woman. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):435-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Sertoli-Leydig cell tumor in a postmenopausal woman.
  • Sertoli-Leydig cell tumor belongs to the group of sex cord-stromal tumors of the ovary.
  • These neoplasms account for less than 0.5% of all ovarian tumors and are more often encountered in young women between the ages of 20 and 30 years who usually become virilized.
  • We described an unusual case of Sertoli-Leydig cell tumor in a postmenopausal women who presented with a solid right pelvic mass, a large amount of ascites, and laboratory tests revealing an elevated CA125, all suggesting a pelvic malignancy.
  • Although five similar cases of postmenopausal women with Sertoli-Leydig cell tumor of ovary have been reported in the literature, we believe that this is an useful addition to the literature.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Sertoli-Leydig Cell Tumor / diagnosis. Sertoli-Leydig Cell Tumor / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Ovariectomy / methods. Postmenopause. Rare Diseases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445673.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Watanabe T, Yamada H, Morimura Y, Abe M, Motoyama T, Sato A: Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report. J Obstet Gynaecol Res; 2008 Jun;34(3):418-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report.
  • Ovarian Sertoli-Leydig cell tumors (SLCT) are rare sex cord stromal neoplasms.
  • To date there have been approximately 25 case reports of ovarian SLCT expressing alpha-fetoprotein (AFP).
  • In such cases, AFP was immunohistochemically detected in the Sertoli cells, Leydig cells, or hepatocytes.
  • A right ovarian tumor was detected and the patient's serum AFP was elevated.
  • On microscopic examination, the tumor was composed of a fibrosarcoma-like area and a poorly differentiated SLCT area with heterologous gastrointestinal epithelium.
  • A recurrent tumor was discovered in the omentum after adjuvant chemotherapy, but serum AFP remained normal.
  • A second laparotomy was performed and the recurrent tumor showed only fibrosarcoma-like features.
  • [MeSH-major] Gastrointestinal Tract / chemistry. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588618.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Azuma A, Koyama T, Mikami Y, Tamai K, Fujimoto K, Morisawa N, Nagano F, Yoshioka S, Togashi K: A case of Sertoli-Leydig cell tumour of the ovary with a multilocular cystic appearance on CT and MR imaging. Pediatr Radiol; 2008 Aug;38(8):898-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Sertoli-Leydig cell tumour of the ovary with a multilocular cystic appearance on CT and MR imaging.
  • We present a case of Sertoli-Leydig cell tumour of the ovary in a 14-year-old girl who presented with abdominal distension.
  • Although extensive cyst formation of Sertoli-Leydig cell tumour is rare, this tumour should be considered in the differential diagnosis of a multilocular cystic ovarian tumour in a young female.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Cysts / diagnosis. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans


26. Rekhi B, Karpate A, Deodhar KK, Chinoy RF: Metastatic rhabdomyosarcomatous elements, mimicking a primary sarcoma, in the omentum, from a poorly differentiated ovarian Sertoli-Leydig cell tumor in a young girl: an unusual presentation with a literature review. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):554-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic rhabdomyosarcomatous elements, mimicking a primary sarcoma, in the omentum, from a poorly differentiated ovarian Sertoli-Leydig cell tumor in a young girl: an unusual presentation with a literature review.
  • Sertoli-Leydig cell tumors (SLCTs) of the ovary with mesenchymal heterologous elements are uncommon.
  • We report an unusual case in a young girl who presented with an omental mass that was consistent with histopathological features of a high-grade sarcoma, with prominent rhabdomyoblastic differentiation of the embryonal type.
  • The sections from her ovarian mass for which she was operated a year back displayed features of a poorly differentiated SLCT with heterologous elements, including focal rhabdomyoblastic differentiation.
  • This is one of the rare cases, to the best of our knowledge, where only rhabomyosarcomatous elements were identified at the metastatic site, mimicking a primary abdominal rhabdomyosarcoma, in a case of an ovarian SLCT.
  • Further, this case reinforces the presence of rhabdomyosarcomatous elements in an ovarian SLCT to be associated with an aggressive disease course.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / secondary. Sertoli-Leydig Cell Tumor / diagnosis
  • [MeSH-minor] Adolescent. Desmin / analysis. Female. Histocytochemistry. Humans. Immunohistochemistry. Keratins / analysis. Omentum / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805972.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Desmin; 68238-35-7 / Keratins
  • [Number-of-references] 10
  •  go-up   go-down


27. Kataria SP, Mishra K, Dev G, Tandon R: Sertoli-Leydig cell tumor of ovary with heterologous element: a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):493-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumor of ovary with heterologous element: a case report.
  • Sertoli-Leydig cell tumors are uncommon tumors of ovary accounting for about 1% of sex cord stromal tumors.
  • They constitute between 0.1% to 0.5% of all the primary ovarian neoplasms.
  • The majority of reported cases are moderately or poorly differentiated combined Sertoli-Leydig cell tumors.
  • A rare case of Sertoli-Leydig cell tumor with heterologous element in a 14 year girl is described.
  • The heterologous component comprised smooth muscle, an uncommon element, that was seen in 60 to 70% of the tumor area.
  • The epithelial element of the tumor consisted of solid, tubular and foci of retiform pattern.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366107.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


28. Young RH: A brief history of the pathology of the gonads. Mod Pathol; 2005 Feb;18 Suppl 2:S3-S17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knowledge of testicular tumor pathology dates back to the great British workers Percival Pott and Sir Astley Cooper but the single greatest early stride was made with the description in 1906 by the French urologist Maurice Chevassu of the seminoma.
  • The seminal 1946 paper of Nathan B Friedman and Robert A Moore, which segregated out as a distinct entity embryonal carcinoma, is, however, the foundation for the current classification of testicular tumors.
  • In that year Pierre Masson described the distinctive neoplasm, the spermatocytic seminoma.
  • The 1950s saw the publication of an important paper by Frank J Dixon and Dr Moore and they also wrote the first series fascicle on testicular tumors.
  • In this same timeframe, and thereafter, Robert E Scully made significant contributions to testicular pathology, writing the first English language paper on spermatocytic seminoma, describing several subtypes of sex cord tumor, and also the distinctive lesion of intersex, the gonadoblastoma, as well as playing a major role in 1980 in formulating the current classification of premalignant lesions of the testis.
  • The current classification of testicular tumors was arrived at in the early 1970s when the World Health Organization, under the leadership of Dr FK Mostofi, who himself made notable contributions to testicular pathology, devised what is fundamentally the current classification of neoplasms of the male gonad.
  • Although comments on ovarian pathology were made by such legendary figures of earlier times as Giovanni Battista Morgagni and Matthew Baillie, it is only in the mid to later years of the 19th century that contributions, mostly in Europe, began to move knowledge of ovarian pathology to its current state.
  • Thomas Hodgkin, Richard Bright, and Sir James Paget all wrote extensively on ovarian neoplasms.
  • In 1870, Heinrich Waldeyer, and later in that century, another German, Hermann Johannes Pfannenstiel wrote important papers on the surface epithelial tumors.
  • Their work was followed by that of Robert Meyer who made monumental contributions to gynecological pathology, including recognizing the Brenner tumor as a distinctive neoplasm and proposing the first classification of Sertoli-Leydig cell tumors (arrhenoblastomas).
  • He also coined the term 'disgerminoma' (soon changed to dysgerminoma) for the ovarian tumor that had been described in detail by the French investigator Marcel Chenot 5 years after Chevassu had mentioned the tumor in his paper describing the seminoma.
  • During the Meyer era other significant contributions were made by, among others, Howard C Taylor writing on the borderline tumors and John A Sampson writing on endometriosis and tumors, associated with it.
  • Dr Teilum delineated the morphologic features of the yolk sac tumor and noted the resemblance of papillary formations within it to the endodermal sinuses of the rat placenta.
  • He also wrote extensively on sex cord tumors in both gonads.
  • At a FIGO meeting in 1961 Dr Santesson played a major role in formulating the first organized classification of the surface epithelial-stromal tumors of the ovary and also promoted the endometrioid carcinoma as a special variant of ovarian cancer.
  • In a career spanning over 50 years, Dr Scully was the architect of the modern classification of ovarian tumors being the driving force behind the influential 1973 World Health Organization classification of them.
  • His many original observations have touched upon virtually all categories of ovarian tumor pathology.
  • His second series fascicle 'Tumors of the Ovaries and Maldeveloped Gonads' utilized the WHO classification and presented a lucid elaboration of his by then vast experience with ovarian tumors.
  • [MeSH-major] Gonads / pathology. Ovarian Neoplasms / history. Pathology / history. Testicular Neoplasms / history

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529187.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Chevassau M; Moore RA; Mostofi FK; Teilum G; Meyer R; Santesson L; Scully RE
  •  go-up   go-down


29. Azurmendi Arín I, Llarena Ibarguren R, Rodríguez JG, Olano Grasa I, Cantón Aller E, Pertusa Peña C: [Sertoli cell malignant tumor]. Arch Esp Urol; 2008 Sep;61(7):834-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sertoli cell malignant tumor].
  • [Transliterated title] Tumor de células de Sertoli maligno.
  • OBJECTIVE: We report a new case of Sertoli cell testicular tumor with malignant characteristics.
  • METHODS: 77 year-old male patient, suffering a general wasting syndrome presenting with a left solid testicular mass with the diagnosis of malignant Sertoli cell tumor after orchyectomy, without local, regional or distant dissemination, and a benign outcome after 18 months of follow-up.
  • RESULTS: Sertoli cell tumor or androblastoma is classified as non-germ cell tumor derived from the stroma of the sexual cords.
  • There are three types depending on its cellular composition: calcified big cell, sclerotic cell, and the most frequent of all, the classic type.
  • CONCLUSIONS: Being the Sertoli cell testicular tumor rare, its malignant type is even rarer, accounting for not more than 10% of all.
  • [MeSH-major] Sertoli Cell Tumor. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972923.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


30. Sachdeva P, Arora R, Dubey C, Sukhija A, Daga M, Singh DK: Sertoli-Leydig cell tumor: a rare ovarian neoplasm. Case report and review of literature. Gynecol Endocrinol; 2008 Apr;24(4):230-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumor: a rare ovarian neoplasm. Case report and review of literature.
  • BACKGROUND: Sertoli-Leydig cell tumor is a gonadal tumor of the sex cord-stromal type.
  • It is a rare tumor comprising 0.1 to 0.5% of all ovarian tumors.
  • A mass the size of a 28-week gravid uterus was arising from the pelvis.
  • A histopathological diagnosis of Sertoli-Leydig cell tumor (intermediate, Meyers type II) was given.
  • CONCLUSION: Patients with Sertoli-Leydig cell tumors present with signs of defeminization followed by masculinization.
  • Age of the patient, stage of the disease and degree of tumor differentiation based on morphology are the most important factors to consider in the management of the case.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis
  • [MeSH-minor] Adolescent. Female. Hirsutism / diagnosis. Hirsutism / etiology. Humans. Ovariectomy. Salpingostomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382911.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Zizi-Sermpetzoglou A, Petrakopoulou N, Tepelenis N, Savvaidou V, Manoloudaki K, Katsoulis M: Pure Sertoli cell tumor. a case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(1):117-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure Sertoli cell tumor. a case report and review of the literature.
  • Pure Sertoli cell tumor (SCT) is a rare sex cord tumor and a subtype of Sertoli-Leydig cell tumors according to the WHO Classification.
  • They lack a Leydig cell component and do not contain the immature neoplastic stroma found in the neoplasms of the Sertoli-Leydig cell category.
  • Sertoli cell tumors occur in women of reproductive age but a few can also occur in children.
  • The tumors are hormone functional in 40-60% of cases.
  • Microscopically they show always almost a tubular growth pattern, but they may also have other growth patterns which can be extensive, making the correct diagnosis difficult.
  • These histologic patterns may result in SCTs mimicking other ovarian tumors.
  • The immunohistochemical panel which usually includes EMA, inhibin, chromogranine, CD99 and calretinin is often helpful in establishing the diagnosis.
  • About 11% of Stage I tumors have worrisome histologic features that may portend an adverse outcome.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349797.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


32. Craig ZR, Davis JR, Marion SL, Barton JK, Hoyer PB: 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide. Comp Med; 2010 Feb;60(1):10-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide.
  • Ovarian cancer is associated with high mortality due to its late onset of symptoms and lack of reliable screening methods for early detection.
  • Furthermore, the incidence of ovarian cancer is higher in postmenopausal women.
  • Mice rendered follicle-depleted through treatment with 4-vinylcyclohexene diepoxide (VCD) are a model of ovary-intact menopause.
  • The present study was designed to induce ovarian neoplasia in this model by treating mice with 7,12-dimethylbenz[a]anthracene (DMBA).
  • Female B6C3F1 mice (age, 28 d) received intraperitoneal sesame oil (vehicle; VCD- groups) as a control or VCD (160 mg/kg; VCD+ groups) daily for 20 d to cause ovarian failure.
  • Four months after the onset of dosing, mice from each group received a single injection of DMBA (VCD-DMBA+ and VCD+DMBA+ groups, n = 15 per group) or vehicle control (VCD-DMBA-, n = 15; VCD+ DMBA-, n = 14) under the bursa of the right ovary.
  • Immunohistochemistry was used to confirm classification of neoplasms.
  • None of the animals in the VCD-DMBA- and VCD-DMBA+ groups (that is, mice still undergoing estrus) had tumors at either time point.
  • At the 3-mo time point, 12.5% of the VCD+DMBA+ mice had ovarian tumors; at 5 mo, 57.1% of the VCD+DMBA+ and 14.3% of VCD+DMBA- ovaries had neoplasms.
  • Neoplasms stained positively for inhibin alpha (granulosa cells) and negatively for keratin 7 (surface epithelium), thus confirming classification of the lesions as Sertoli-Leydig cell tumors.
  • These findings provide evidence for an increased incidence of DMBA-induced ovarian neoplasms in the ovaries of follicle-depleted mice compared with that in age-matched cycling controls.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINYLCYCLOHEXENE DIOXIDE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Lett. 2001 Mar 31;120(1-3):199-208 [11323178.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79 [17018256.001]
  • [Cites] Endocrinology. 2001 Aug;142(8):3673-84 [11459817.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1489-95 [11673266.001]
  • [Cites] Histopathology. 2002 Apr;40(4):309-26 [11943015.001]
  • [Cites] Endocrinology. 2003 Jan;144(1):69-74 [12488331.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):327-34 [12584184.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):130-8 [14998904.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:67 [14613552.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1747-55 [15073042.001]
  • [Cites] Gan. 1967 Jun;58(3):253-66 [6081229.001]
  • [Cites] Int J Cancer. 1969 Jan 15;4(1):61-75 [4310334.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] Cancer Res. 1973 Apr;33(4):721-3 [4696472.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2768-73 [4748432.001]
  • [Cites] Gynecol Oncol. 1977 Jun;5(2):161-7 [881128.001]
  • [Cites] Cancer Res. 1984 May;44(5):1827-30 [6713385.001]
  • [Cites] Carcinogenesis. 1984 Aug;5(8):1021-6 [6430583.001]
  • [Cites] Arch Histol Jpn. 1986 Aug;49(3):379-89 [3800599.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:91-106 [3665872.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] Cell. 1990 Oct 5;63(1):175-83 [1698554.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):394-401 [8806857.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jul;293(1):F193-9 [17389681.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):99-109 [18234966.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):301-21 [18368558.001]
  • [Cites] J Bone Miner Res. 2008 Aug;23(8):1296-303 [18348702.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):610-5 [19150572.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R587-92 [19439618.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23963-8 [10446164.001]
  • [Cites] J Exp Zool. 1957 Mar;134(2):207-37 [13428952.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1963;19:779-82 [14050667.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8177-83 [15548682.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):951-7 [15695234.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1910-6 [15994440.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1765-6 [16127026.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):117-24 [15902502.001]
  • [Cites] Comp Med. 2005 Dec;55(6):523-7 [16422148.001]
  • [Cites] Menopause. 2006 May-Jun;13(3):482-8 [16735946.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):041123 [16965151.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):87-93 [11420227.001]
  • (PMID = 20158943.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NCI NIH HHS / CA / R01 CA119200; United States / NIA NIH HHS / AG / AG021948; United States / NIA NIH HHS / AG / R01 AG021948; United States / NCI NIH HHS / CA / CA119200
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cyclohexenes; 0 / Keratin-7; 0 / Krt2-7 protein, mouse; 0 / Vinyl Compounds; 0 / inhibin-alpha subunit; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 57285-09-3 / Inhibins; 596C064IG4 / 4-vinyl-1-cyclohexene dioxide
  • [Other-IDs] NLM/ PMC2826079
  •  go-up   go-down


33. Stacher E, Pristauz G, Scholz HS, Moinfar F: Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report. Int J Gynecol Pathol; 2010 Sep;29(5):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report.
  • Bilateral Sertoli-Leydig cell tumors (SLCTs) of the ovary, especially in association with a cystadenoma, are exceedingly rare.
  • We present a case of a 61-year-old woman with bilateral well-differentiated SLCTs in which the Sertoli-Leydig cell component showed leiomyogenic (heterologous) differentiation.
  • [MeSH-major] Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Cell Differentiation. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2011 Jul;30(4):395 [21623193.001]
  • (PMID = 20736765.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Schneider DT, Calaminus G, Harms D, Göbel U, German Maligne Keimzelltumoren Study Group: Ovarian sex cord-stromal tumors in children and adolescents. J Reprod Med; 2005 Jun;50(6):439-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sex cord-stromal tumors in children and adolescents.
  • Ovarian sex cord-stromal tumors (OSCSTs) are a heterogeneous group of tumors that develop from the gonadal non-germ-cell component.
  • Despite recent advances in the clinical and histopathologic diagnosis of OSCSTs, a high degree of uncertainty remains with regard to adequate therapy, particularly in patients presenting with microscopic or macroscopic tumor spread.
  • In addition, we summarize the data from our clinical, histopathologic and genetic analyses of patients that were prospectively reported to the German MAKEI protocols for treatment of nontesticular malignant germ cell tumors.
  • Among these patients, juvenile granulosa cell tumors (JGCTs) constitute the most frequent histologic subtype, followed by Sertoli-Leydig cell tumors (SLCTs) and sclerosing stromal tumors.
  • In addition, prognosis correlates with tumor stage according to the International Federation of Obstetrics and Gynecology.
  • Nevertheless, we observed a favorable response to cisplatin-based chemotherapy in the majority of stage II and III tumors.
  • Genetic analysis of 27 tumors available for comparative genomic hybridization analysis revealed normal profiles in the majority of tumors and whole chromosomal gain, such as a gain of 12 in single tumors, with no consistent pattern with regard to histology or clinical outcome.
  • This analysis confirmed that most OSCSTs present at a low tumor stage and that prognosis in these patients is excellent.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy. Sex Cord-Gonadal Stromal Tumors / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Germany. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050568.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


35. Young RH: Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol; 2005 Feb;18 Suppl 2:S81-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.
  • Gonadal sex cord-stromal tumors contain some of the most morphologically interesting neoplasms of the gonads and these lead to many important issues in differential diagnosis.
  • The pathology of these tumors is reviewed with emphasis on new information, similarities and differences in the two gonads, and diagnostic problems.
  • Sertoli cell tumors occur in both gonads being more common in the testis where they usually exhibit a lobular pattern of hollow or solid tubules.
  • In the ovary, tubular differentiation is usually the predominant feature but the lobulation typically seen in the testis is generally not as striking.
  • One variant of Sertoli cell tumor, the large cell calcifying form, appears to be restricted to the male gonad and in contrast to other sex cord tumors is much more frequently bilateral and is associated in many cases with unusual clinical manifestations.
  • In females, it is in the form of the sex cord with annular tubules whereas in males, the lesion has features that are often intermediate between those of a sex cord tumor with annular tubules and a large cell calcifying Sertoli cell tumor.
  • Sertoli-Leydig cell tumors are more morphologically diverse than pure Sertoli cell tumors and for practical purposes are an issue only in ovarian pathology being exceptionally rare in the testis.
  • The classification proposed by Meyer into well, intermediate, and poor differentiation, remains important prognostically.
  • Heterologous tumors most often contain mucinous epithelium, sometimes with small foci of carcinoid or less commonly, and generally in poorly differentiated neoplasms, rhabdomyosarcoma or fetal-type cartilage.
  • Such tumors should be distinguished from pure sarcomas and teratomas.
  • The retiform neoplasms, which tend to occur in young females, may mimic serous borderline tumors or even serous carcinomas.
  • Granulosa cell tumors are much more common in females and in both gonads are divided into adult and juvenile forms.
  • In females, granulosa cell tumors and other sex cord tumors may have markedly bizarre nuclei potentially leading to overdiagnosis as more malignant neoplasms.
  • The juvenile granulosa cell tumor of the testis tends to occur in the first 6 months of life and should be carefully distinguished from the yolk sac tumor of the testis, which usually occurs in a slightly older age group.
  • Occasional sex cord-stromal tumors cannot be readily categorized into the Sertoli or granulosa families and are diagnosed as sex cord-stromal tumors unclassified.
  • In females, this is a relatively common placement for a neoplasm in a pregnant patient.
  • Unclassified tumors are overall more common in males and may entrap residual normal germ cells potentially leading to the erroneous placement of the tumor in the category of a mixed germ cell sex cord-stromal tumor.
  • From the practical viewpoint, the most helpful immunohistochemical findings are the negative staining of sex cord tumors for epithelial membrane antigen, and positive staining for inhibin and calretinin, findings that are converse to those seen in endometrioid carcinomas of the ovary, which commonly have formations that simulate sex cord tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Granulosa Cell Tumor / pathology. Humans. Male. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502809.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


36. Llarena Ibarguren R, Azurmendi Sastre V, Padilla Nieva J, Pertusa Peña C: [Non germinal cell testicular tumors]. Arch Esp Urol; 2005 Dec;58(10):1031-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non germinal cell testicular tumors].
  • [Transliterated title] Tumores no germinales de testículo.
  • OBJECTIVES: We report a review of all patients with testicular tumors undergoing surgery in our Hospital over a 13 year period.
  • There were 151 cases, 50 of them were reported as non germ cell tumors (33%).
  • METHODS/RESULTS: 42% of them were haematopoietic tumors, lymphomas and leukemias.
  • 30% of them were non neoplastic tumors, including vascular tumors and granulomatous orchitis.
  • 12% were identified as Leydig or Sertoli cell tumors.
  • CONCLUSIONS: Non germ cell tumors were more frequent in adults (78%) than in children (22%).

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482852.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


37. Rivera-Arkoncel ML, Pacquing-Songco D, Lantion-Ang FL: Virilising ovarian tumour in a woman with an adrenal nodule. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilising ovarian tumour in a woman with an adrenal nodule.
  • Androblastomas of the ovary comprise less than 0.5% of all ovarian tumours.
  • Pure Leydig cell tumours are very rare and almost always show secretion of male sex hormones.
  • A low dose dexamethasone suppression test suggested an ovarian source.
  • Doppler transvaginal ultrasound revealed a solid lobulated structure in the right ovary.
  • The patient underwent surgery and histopathology showed a Leydig cell tumour, hilar type.
  • Specific clinical and biochemical investigation of androgen secreting neoplasms is very important for correct diagnosis of these rare tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3074-7 [12107203.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2634-43 [12788867.001]
  • [Cites] Endocr Pract. 2001 Mar-Apr;7(2):120-34 [12940239.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):453-62 [14764747.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):187-97 [7237384.001]
  • [Cites] Gynecol Endocrinol. 2005 Oct;21(4):238-41 [16316848.001]
  • [Cites] N Engl J Med. 2005 Dec 15;353(24):2578-88 [16354894.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):2-6 [16263820.001]
  • (PMID = 22802276.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Androblastoma of ovary
  • [Other-IDs] NLM/ PMC3029143
  •  go-up   go-down


38. Youssef A, Ben Ghezala M, Oueslati A, Agrebi W, Oueslati H: [Sertoli-Leydig cell tumor of the ovary]. Tunis Med; 2006 Mar;84(3):209-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sertoli-Leydig cell tumor of the ovary].
  • [Transliterated title] Les tumeurs de Sertoli-Leydig de l'ovaire.
  • Sertoli-Leidig cell tumor of the ovary is a rare tumor.
  • It accounts for 0.5 - 1% of all ovarian tumors.
  • Sertoli-Leidig cell tumors are commonly benign and they occur in young women who desire further childrearing.
  • For the malign Sertoli-Leidig cell tumor, radical treatment is required.
  • The aim of this work is the analysis of clinical, para-clinical and therapeutic aspects of these tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755966.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


39. Sala E, Villa N, Crosti F, Miozzo M, Perego P, Cappellini A, Bonazzi C, Barisani D, Dalprà L: Endometrioid-like yolk sac and Sertoli-Leydig cell tumors in a carrier of a Y heterochromatin insertion into 1qh region: a causal association? Cancer Genet Cytogenet; 2007 Mar;173(2):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid-like yolk sac and Sertoli-Leydig cell tumors in a carrier of a Y heterochromatin insertion into 1qh region: a causal association?
  • We describe the case of a young woman showing yolk sac tumors (YST) and a Sertoli-Leydig cell tumor (SLCT) in the right ovary, with recurrences in the right adnexum and with hepatic metastasis.
  • To our knowledge, YST and SLCT have never been described as components of the same tumor or reported as associated in the same patient.
  • LOH analysis revealed 1p36 paternal allele loss in the proband tumor, thus supporting a germ cell origin for the tumor.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Y. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321334.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterochromatin
  •  go-up   go-down


40. Shi JL, Guo LN, Lang JH: [Advances in Sertoli-Leydig cell tumour of the ovary]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):631-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in Sertoli-Leydig cell tumour of the ovary].
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovary / pathology. Proto-Oncogene Proteins / metabolism. Proto-Oncogenes / immunology. Sertoli-Leydig Cell Tumor / pathology. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094590.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Lectures
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


41. Riggs JC, Zarghami F, Najid K, Haber K, Schreffler SM: Postpartum hemorrhage from ruptured Sertoli-Leydig cell tumor: a case report. J Reprod Med; 2010 Sep-Oct;55(9-10):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postpartum hemorrhage from ruptured Sertoli-Leydig cell tumor: a case report.
  • BACKGROUND: Spontaneous postpartum rupture of a Sertoli-Leydig cell ovarian tumor is an infrequent complication of a rare tumor.
  • CASE: A 21-year-old nullipara with an uneventful prenatal course and spontaneous vaginal delivery experienced severe intraabdominal bleeding with hypovolemic shock postpartum from the rupture of a previously undiagnosed Sertoli-Leydig cell ovarian tumor.
  • Diagnosis and intervention were delayed because of the late development of overt signs of intraabdominal bleeding and misleading findings on abdominal examination.
  • CONCLUSION: Rupture of a Sertoli-Leydig cell tumor is a potential cause of postpartum hypovolemic shock resulting from massive intraabdominal bleeding.
  • [MeSH-major] Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Postpartum Hemorrhage / etiology. Sertoli-Leydig Cell Tumor / complications. Sertoli-Leydig Cell Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043371.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol; 2007 Feb;104(2):396-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.
  • OBJECTIVE: To evaluate prognostic factors that impact on the survival of women with ovarian sex cord stromal tumors (SCST).
  • METHODS: Data including age at diagnosis, stage, histology, grade, treatment, and survival were extracted from the 1988-2001 Surveillance, Epidemiology, and End Results Program.
  • RESULTS: 376 women (median age: 51) with ovarian sex cord stromal cell tumors were identified, including 339 with granulosa cell and 37 with Sertoli-Leydig cell tumors.
  • 265 (71%) patients had stage I, 39 (10%) stage II, 40 (11%) stage III, and 32 (8%) had stage IV disease.
  • Women with stage I-II disease had a 5-year disease-specific survival of 95% compared to 59% in those with stage III-IV cancers (p<0.001).
  • 110 patients with stage I-II disease underwent conservative surgery without hysterectomy.
  • On multivariate analysis, age<or=50 (p=0.001) and early-stage disease (p<0.001) remained significant prognostic factor for improved survival.
  • CONCLUSIONS: Younger age and early-stage disease are important predictors for improved survival in patients with ovarian sex cord stromal tumors.
  • [MeSH-major] Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030354.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. McCluggage WG, Young RH: Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol; 2007 Apr;31(4):592-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors).
  • The propensity for ovarian endometrioid adenocarcinomas to morphologically mimic Sertoli, Sertoli-Leydig, and granulosa cell tumors, is well known.
  • The converse situation, mimicry of an endometrioid neoplasm by a sex cord-stromal tumor, has not been emphasized.
  • In this report, we describe 9 ovarian Sertoli-Leydig cell tumors (5 well differentiated, 4 of intermediate differentiation) with areas containing hollow, sometimes dilated, tubules which resemble endometrioid glands; we refer to these as pseudoendometrioid tubules.
  • The tumors, all of which were unilateral except for one, ranged from 3.5 to 19 cm and were variously described as tan, pale, yellow, or gold.
  • The proportion of the tumor made up of pseudoendometrioid tubules ranged from 10% to >90%.
  • When widespread, their presence sometimes resulted in consideration of a borderline endometrioid adenofibroma or a well-differentiated endometrioid adenocarcinoma.
  • However, all the neoplasms contained typical Sertoli tubules and one or more of the characteristic patterns of Sertoli-Leydig cell tumors as well as Leydig cells, although the latter cells were inconspicuous in some cases.
  • Immunohistochemistry, performed in 4 cases, showed that the pseudoendometrioid tubules, as well as the more typical Sertoli cell elements, were either positive for alpha inhibin (3 of 4 cases) or calretinin (3 of 4 cases) or both, although sometimes focally so.
  • This report illustrates the potential for ovarian Sertoli-Leydig cell tumors to contain tubules with a pseudoendometrioid appearance which mimic a borderline or malignant endometrioid neoplasm.
  • The presence of more typical Sertoli cell elements and Leydig cells, an absence of squamous elements, endometriosis or associated adenofibroma, and the characteristic immunophenotype assist in diagnosis.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414107.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Jarzabek K, Philibert P, Koda M, Sulkowski S, Kotula-Balak M, Bilinska B, Kottler ML, Wolczynski S, Sultan C: Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor. Gynecol Endocrinol; 2007 Sep;23(9):499-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
  • The present paper describes a new de novo non-sense mutation in exon 1 (K141Z) of the androgen receptor gene (AR) and the expression in CAIS testis of aromatase, estrogen receptors, as well as proliferation- and apoptosis-associated proteins.
  • CAIS is a rare disease characterized by absent virilization in 46,XY individuals and the development of a female phenotype despite normal or even elevated androgen levels.
  • Testicular tumors such as Sertoli-Leydig cell tumor often develop in patients with CAIS.
  • The immunohistochemical findings in the testes of our CAIS patient suggest that the high expression of aromatase and other molecular changes in the testis may be responsible for pubertal breast development and the increased risk of testicular tumor.
  • [MeSH-major] Amenorrhea / etiology. Androgen-Insensitivity Syndrome / complications. Androgen-Insensitivity Syndrome / genetics. Apoptosis / genetics. Aromatase / metabolism. Receptors, Androgen / genetics. Sertoli-Leydig Cell Tumor / complications. Testicular Neoplasms / complications


45. Farinola MA, Gown AM, Judson K, Ronnett BM, Barry TS, Movahedi-Lankarani S, Vang R: Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol; 2007 Oct;26(4):375-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
  • The biologic role that estrogen receptor (ER) and progesterone receptor (PR) play in ovarian sex cord-stromal tumors is poorly understood.
  • Furthermore, immunohistochemical data on these hormone receptors in this group of neoplasms are limited and conflicting, with many reports suggesting that expression of ERalpha and/or PR is either infrequent or present at low levels in granulosa and Sertoli cell tumors.
  • Immunohistochemical staining for ERalpha and PR was performed in 69 ovarian sex cord-stromal tumors: 41 adult granulosa cell tumors and 28 Sertoli-Leydig cell tumors.
  • Estrogen receptor alpha and PR were frequently expressed in adult granulosa cell tumors (66% and 98%, respectively) and Sertoli-Leydig cell tumors (79% and 86%, respectively).
  • Diffuse (3+ or 4+) expression of PR was more common in adult granulosa cell tumors (68% vs. 36%; P = 0.013), whereas diffuse (3+ or 4+) expression of ERalpha was more frequent in Sertoli-Leydig cell tumors (50% vs. 20%; P = 0.010).
  • In cases positive for both markers, adult granulosa cell tumors exhibited a focal (1+ or 2+) ERalpha/diffuse (3+ or 4+) PR coordinate profile more commonly than Sertoli-Leydig cell tumors (52% vs. 18%; P = 0.02), whereas Sertoli-Leydig cell tumors displayed a diffuse (3+ or 4+) ERalpha/focal (1+ or 2+) PR profile more frequently than adult granulosa cell tumors (36% vs. 0%; P = 0.0007).
  • We conclude that expression of hormone receptors (based only on frequency of immunostaining) does not allow for distinction from other tumors in the differential diagnosis that are known to be frequently positive for ERalpha and PR such as endometrioid neoplasms.
  • Most adult granulosa cell tumors and Sertoli-Leydig cell tumors share overlapping patterns of expression of ERalpha and PR with each other, but a subset of cases in each tumor category exhibits unique ERalpha/PR immunoprofiles (eg, focal ERalpha/diffuse PR in adult granulosa cell tumors and diffuse ERalpha/focal PR in Sertoli-Leydig cell tumors).
  • These patterns of expression of ERalpha and PR may aid our understanding of the biologic differences between granulosa and Sertoli cell tumors.
  • [MeSH-major] Estrogen Receptor alpha / biosynthesis. Granulosa Cell Tumor / metabolism. Ovarian Neoplasms / metabolism. Receptors, Progesterone / biosynthesis. Sertoli-Leydig Cell Tumor / metabolism
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885486.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone
  •  go-up   go-down


46. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • A number of histologic features can be used to distinguish the 2 entities, the most important ones being (1) the presence of areas with the usual pattern of endometrioid carcinoma, and (2) the presence of mucin at the apical borders of the tumor cells.
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L: Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol; 2008 Jan;31(1):85-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors.
  • OBJECTIVE: To describe the clinical history and ultrasound findings in women with ovarian Sertoli cell, Sertoli-Leydig cell and Leydig cell tumors.
  • METHODS: Women with a histological diagnosis of Sertoli cell tumor, Sertoli-Leydig cell tumor or Leydig cell tumor who had undergone preoperative ultrasound examination were identified from the databases of each of three participating ultrasound centers.
  • The tumors were characterized on the basis of ultrasound images, ultrasound reports and research protocols (when applicable) using the terms and definitions published by the International Ovarian Tumor Analysis (IOTA) group.
  • RESULTS: Of 22 patients identified, 15 had Sertoli-Leydig cell tumors, two had Sertoli cell tumors and five had Leydig cell tumors.
  • Twenty-two (96%) of 23 tumors (one woman had bilateral tumors) contained a solid component; 16 (70%) were purely solid.
  • Pattern recognition showed that the Leydig cell tumors were small solid tumors (four of five had a largest diameter of 1-3 cm) and the two Sertoli cell tumors were somewhat larger solid tumors (4 cm and 7 cm); the Sertoli-Leydig cell tumors were either small (3-4 cm) or medium-sized (6-7 cm) solid tumors, or multilocular solid tumors of any size (3-18 cm) with purely solid areas mixed with areas of innumerable closely packed small cyst locules.
  • CONCLUSIONS: On the basis of endocrine symptoms, the woman's age and ultrasound findings, it should be possible to suggest a correct preoperative diagnosis of Sertoli cell, Sertoli-Leydig cell or Leydig cell tumors in many cases.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Cell Differentiation / physiology. Female. Humans. Middle Aged. Pattern Recognition, Automated / methods. Prognosis

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 18098335.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Oliva E, Garcia-Miralles N, Vu Q, Young RH: CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int J Gynecol Pathol; 2007 Oct;26(4):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases.
  • CD10 has been recently advocated as a good immunohistochemical marker for endometrial stromal tumors.
  • Metastatic endometrial stromal tumors to the ovary and primary endometrioid stromal sarcomas may show overlapping histological features with pure stromal and sex cord-stromal tumors (SCSTs).
  • We investigated CD10 expression in a large series of pure stromal and SCSTs of the ovary to ascertain whether CD10 may aid in this differential diagnosis.
  • Archival material from 11 fibromas, 10 thecomas, 10 sclerosing stromal tumors (SSTs), 10 adult granulosa cell tumors (AGCTs), 4 luteinized AGCTs, 9 juvenile granulosa cell tumors (JGCTs), 9 Sertoli cell tumors, 9 Sertoli-Leydig cell tumors, 11 sex cord tumors with annular tubules, 10 steroid cell tumors (StCTs), and 8 fibrosarcomas of the ovary were immunostained for CD10.
  • CD10 was expressed in 7 of 10 thecomas (4 with 5%-75% and mostly 1+), 9 of 10 SSTs (7 with 5%-39% + cells, mostly 1+), 9 of 10 AGCTs (<5%-39%, four 1+, five 2+), 1 of 4 luteinized AGCTs (<5% and 1+), 8 of 9 JGCTs (mostly <5% to 39% and +1), 4 of 9 Sertoli cell tumors (either focal or >75% with variable intensity), 4 of 9 Sertoli-Leydig cell tumors (mostly <10% with variable staining), with the Leydig cells being positive in only 1 tumor (1+ and <5%), and 7 of 10 StCTs (4 tumors with more than 75% + cells, from 1+ to 3+).
  • All fibromas, all but 1 fibrosarcoma (<5% and 1+), and all sex cord tumors with annular tubules were CD10 negative.
  • CD10 expression was frequently seen in StCTs, SSTs, and thecomas of the ovary, although the latter 2 categories usually showed only faint immunoreactivity.
  • In conclusion the frequency and intensity of CD10 immunoreactivity in pure stromal and sex cord-stromal ovarian tumors are low and contrast with the typical strong and diffuse immunostaining seen in endometrial stromal tumors; however, faint CD10 positivity is consistent with the diagnosis of ovarian SCST.
  • Steroid cell tumors are often positive for CD10, but these tumors do not pose problems in differential diagnosis with endometrial stromal tumors.
  • CD10 may play a useful role in aiding the differential between endometrial stromal tumors in the ovary and SCST and stromal tumors.
  • [MeSH-major] Neprilysin / biosynthesis. Ovarian Neoplasms / metabolism. Sex Cord-Gonadal Stromal Tumors / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrial Stromal Tumors / pathology. Female. Humans. Immunohistochemistry. Pregnancy. Pregnancy Complications, Neoplastic / metabolism. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885484.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


49. Poli UR, Swarnalata G, Maturi R, Rao ST: Recurrent alpha-fetoprotein secreting Sertoli-Leydig cell tumor of ovary with an unusual presentation. Indian J Cancer; 2009 Jan-Mar;46(1):64-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent alpha-fetoprotein secreting Sertoli-Leydig cell tumor of ovary with an unusual presentation.
  • Alpha-fetoprotein secreting (AFP) Sertoli-Leydig cell tumors of ovary (SLCT) are now identified as a distinct entity among the uncommon group of sex cord tumors of ovary.
  • We report an unusual case of recurrent AFP secreting ovarian tumors and as ileocecal mesenteric cyst in a 25-year-old patient resulting in difficulty in initial diagnosis of AFP producing SLCT.
  • [MeSH-major] Cecal Neoplasms / pathology. Ileal Neoplasms / pathology. Leydig Cell Tumor / metabolism. Mesenteric Cyst / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / metabolism. Sertoli Cell Tumor / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282570.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


50. McKenna M, Kenny B, Dorman G, McCluggage WG: Combined adult granulosa cell tumor and mucinous cystadenoma of the ovary: granulosa cell tumor with heterologous mucinous elements. Int J Gynecol Pathol; 2005 Jul;24(3):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adult granulosa cell tumor and mucinous cystadenoma of the ovary: granulosa cell tumor with heterologous mucinous elements.
  • We describe an unusual ovarian neoplasm in a 57-year-old woman composed of an admixture of mucinous cystadenoma and adult granulosa cell tumor (AGCT).
  • Theories of histogenesis include a collision tumor and heterologous mucinous differentiation within an AGCT.
  • Because heterologous mucinous elements are well described in other ovarian sex-cord-stromal neoplasms, especially but not exclusively Sertoli Leydig cell tumors, it is not unexpected that a similar phenomenon could occur in an AGCT.
  • We review the previously reported cases of combined mucinous cystadenoma and granulosa cell tumor of the ovary.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2012 Jul;31(4):335-6 [22653346.001]
  • (PMID = 15968196.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


51. Howell L, Bader A, Mullassery D, Losty P, Auth M, Kokai G: Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome. Pediatr Blood Cancer; 2010 Jul 15;55(1):206-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome.
  • We report a case of Peutz-Jeghers syndrome (PJS) in a 2-year old with precocious puberty secondary to a Sertoli-Leydig cell tumour.
  • The tumour was excised and the STK11 gene deletion identified in both patient and father.
  • [MeSH-major] Gastric Mucosa / pathology. Hamartoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / diagnosis. Polyps / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20310004.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


52. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • SLCT with benign and borderline mucinous neoplasm has been reported in the literature.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • She presented with throbbing lower abdominal pain and was found to have a large, complex left ovarian mass on imaging studies.
  • Gross examination of the surgical specimen showed a large, encapsulated, solid-cystic mass completely replacing the ovary.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • The histopathological features and results of immunostaining were consistent with the diagnosis of the intermediately differentiated SLCT with mucinous adenocarcinoma as the heterologous element.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Cell Differentiation. Female. Humans. Immunohistochemistry. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement